Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and ...

For the US, it means that the UK will spend more on medicines and offer more support to industry. Over the next ten years, ...

In this exclusive video interview, pharmaphorum’s editor-in-chief Jonah Comstock sits down with Carlos Buesa, CEO of Oryzon ...

Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement ...

Former Moderna executive Dr Melanie Ivarsson has been appointed chief executive of the UK's Health Data Research Service ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

AbbVie has joined many of its big pharma peers by signing a Most-Favoured Nation (MFN) drug pricing deal with the Trump ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

The US regulator has approved Sentynl Therapeutics Zycubo (copper histidinate; formerly known as CUTX-101) as a treatment for ...